Colorectal cancer is the second leading cause of cancer-related mortality in the United States. More than 50% of patients with colorectal cancer will develop liver metastases in their lifetime with a dismal <10% surviving past three years. A major therapeutic problem in this disease is that no markers prognostic of hepatic recurrence or predictive of response prior to treatment are known. The goal of this research is to fill this gap by providing non-invasive and objective prognostic quantitative imaging markers for personalized treatment of colorectal liver metastases (CRLM). Our single-institution data support that quantitative imaging features extracted from routine CT scans predict volumetric response to systemic and regional chemotherapy and identify patients at high risk of hepatic recurrence and poor survival. Progress in developing these novel markers is limited by a lack of optimization, standardization, and validation, all critical barriers to clinical use. The objectives of this application are to develop and validate robust imaging features by standardizing image acquisition, to improve automated tools for clinical trial use, and to validate the predictive power of imaging features with external data. We have partnered with University of Texas MD Anderson Cancer Center, Rensselaer Polytechnic Institute, and GE Research, facilitating the widespread integration of the proposed technology into medical centers worldwide. Our central hypothesis is that quantitative CT-based imaging features provide novel and robust indices for predicting response, hepatic recurrence, and survival in CRLM patients. Specifically, we will (1) validate predictive and prognostic imaging features with external data, (2) prospectively assess repeatability and reproducibility of contrast-enhanced CT imaging features, and (3) develop an integrated rawdiomics pipeline by fully utilizing sinogram data. We have assembled a critical mass of experts in surgery, medical oncology, pathology, radiology, biostatistics, and image analysis. Combined with the largest clinical experience in CRLM in the western world, this application is a unique and unrivaled opportunity to define radiomics of CRLM. Integration into existing clinical workflows means that small medical centers without highly specialized radiology groups would benefit from predictive algorithms developed at two high-volume centers via a low-cost software update. Successful completion of our aims will provide validated prognostic imaging markers with a pathway to routine clinical use, which are of paramount importance to improving patient survival of this deadly disease.

Public Health Relevance

Improvements in the resolution of CT imaging over a decade ago have created an abundance of data that contain information invisible to the human eye, which can be capitalized upon to create predictive treatment algorithms. This proposal aims to validate, optimize, and standardize our novel CT-based imaging markers that predict response to therapy, hepatic recurrence, and survival in patients with colorectal liver metastases. These findings will help us move from the ?treat everyone to help a few? paradigm of cancer care to fulfill the promise of precision medicine and improve the cure rate for colorectal cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA233888-02
Application #
9878820
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Menkens, Anne E
Project Start
2019-03-01
Project End
2024-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
2
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065